[1]. Effect of Butyrate-Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab
(2026年) [査読] 有
[2]. Validation study of age-independent fibrosis score (Fibrosis-3 index) in patients with metabolic dysfunction-associated steatotic liver disease
HEPATOLOGY RESEARCH (2024年) [査読] 有
[3]. A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis
HEPATOLOGY (2024年) [査読] 有
[4]. Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: A multicenter study in Japan
Alimentary Pharmacology & Therapeutics (2024年) [査読] 有
[5]. Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma
Cancer reports (Hoboken, N.J.) (2024年) [査読] 有